secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2023-03-17T23:59:59+00:00
Accession:  0001493152-23-008009
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Therapeutics Q4/FY2022: Loss per share $1.73, cash $26.4M; Phase 1 Decoy20 trial underway
--------------------------------------------------------------------------------

- R&D expense $1.9M in Q4 (up 90% YoY); FY R&D $6.3M (up 150% YoY).
- Cash and marketable securities $26.4M as of Dec 31, 2022; runway into Q2 2024.
- First patient dosed in Phase 1 Decoy20 trial for solid tumors in March 2023; three sites activated.
- Net cash used in operations $13.1M for FY2022 vs $11.3M in FY2021.
- Robert Martell, M.D., Ph.D. elected to Board in February 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223008009/0001493152-23-008009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223008009/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-008009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer